SCHEMBL5201709

SCHEMBL5201709

COc1cc2nccc(Oc3cc(C)c(NC(=O)Nc4ccc(Cl)cc4C)cc3C)c2cc1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 18/20 0.64
KDR P35968 18/20 0.64
SRC P12931 2/20 0.55
KIT P10721 2/20 0.55
RIPK2 O43353 1/20 0.55
STK10 O94804 1/20 0.55
ABL1 P00519 1/20 0.55
LCK P06239 1/20 0.55
LYN P07948 1/20 0.55
RET P07949 1/20 0.55
MET P08581 1/20 0.55
PDGFRB P09619 1/20 0.55
BCR P11274 1/20 0.55
FGFR1 P11362 1/20 0.55
FLT1 P17948 1/20 0.55
MAPK3 P27361 1/20 0.55
HTR2A P28223 1/20 0.55
MAPK1 P28482 1/20 0.55
EPHA2 P29317 1/20 0.55
EPHB2 P29323 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5201774 0.89 PDGFRA (0.62) PDGFRAKDRSRCKITRIPK2
SCHEMBL5207860 0.88 PDGFRA (0.73) PDGFRAKDRSRCKITMET
SCHEMBL5240346 0.88 PDGFRA (0.74) PDGFRAKDRSRCKITLCK
SCHEMBL6864459 0.87 KDR (0.84) PDGFRAKDR
SCHEMBL5201453 0.86 PDGFRA (0.70) PDGFRAKDRSRCKITTGFBR1
SCHEMBL5204991 0.85 KDR (0.80) PDGFRAKDRSRCKITRET
SCHEMBL5825131 0.85 PDGFRA (0.48) PDGFRAKDRSRCMETPDGFRB
SCHEMBL5208717 0.84 PDGFRA (0.76) PDGFRAKDR
SCHEMBL5208202 0.84 PDGFRA (0.55) PDGFRAKDRSRCKITRIPK2
SCHEMBL5824978 0.83 SRC (0.60) PDGFRAKDRSRCKITMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1384712-B1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BREWERY (JP) 2007-03-07 EP disclosed
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-02-01 US disclosed
US-7169789-B2 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-01-30 US disclosed
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-10-21 US disclosed
US-6797823-B1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-09-28 US disclosed
EP-1384712-A1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BEER KABUSHIKI KAISHA (JP) 2004-01-28 EP disclosed
EP-1153920-B1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BREWERY (JP) 2003-10-29 EP disclosed
EP-1153920-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BEER KABUSHIKI KAISHA (JP) 2001-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives CYTH3, NQO2, NRAS PDGFRA 3108/4885KDR 2466/4885SRC 3065/4885
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives RABL3, NRAS, CYTH3 PDGFRA 3103/4885KDR 3106/4885SRC 2612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.